These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 18221026)

  • 1. Novel checkpoint 1 inhibitors.
    Prudhomme M
    Recent Pat Anticancer Drug Discov; 2006 Jan; 1(1):55-68. PubMed ID: 18221026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitors of the G2 DNA damage checkpoint and their potential for cancer therapy.
    Anderson HJ; Andersen RJ; Roberge M
    Prog Cell Cycle Res; 2003; 5():423-30. PubMed ID: 14593736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug discovery targeting Chk1 and Chk2 kinases.
    Zhou BB; Sausville EA
    Prog Cell Cycle Res; 2003; 5():413-21. PubMed ID: 14593735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chk1 inhibitors for novel cancer treatment.
    Tao ZF; Lin NH
    Anticancer Agents Med Chem; 2006 Jul; 6(4):377-88. PubMed ID: 16842237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitors of checkpoint kinases: from discovery to the clinic.
    Janetka JW; Ashwell S; Zabludoff S; Lyne P
    Curr Opin Drug Discov Devel; 2007 Jul; 10(4):473-86. PubMed ID: 17659489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting serine/threonine protein kinase B/Akt and cell-cycle checkpoint kinases for treating cancer.
    Li Q; Zhu GD
    Curr Top Med Chem; 2002 Sep; 2(9):939-71. PubMed ID: 12171565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage.
    Jackson JR; Gilmartin A; Imburgia C; Winkler JD; Marshall LA; Roshak A
    Cancer Res; 2000 Feb; 60(3):566-72. PubMed ID: 10676638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Checkpoint kinase inhibitors: a patent review (2009 - 2010).
    Lainchbury M; Collins I
    Expert Opin Ther Pat; 2011 Aug; 21(8):1191-210. PubMed ID: 21599421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining DNA damaging agents and checkpoint 1 inhibitors.
    Prudhomme M
    Curr Med Chem Anticancer Agents; 2004 Sep; 4(5):435-8. PubMed ID: 15379699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The checkpoint 1 kinase inhibitor LY2603618 induces cell cycle arrest, DNA damage response and autophagy in cancer cells.
    Wang FZ; Fei HR; Cui YJ; Sun YK; Li ZM; Wang XY; Yang XY; Zhang JG; Sun BL
    Apoptosis; 2014 Sep; 19(9):1389-98. PubMed ID: 24928205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New opportunities in chemosensitization and radiosensitization: modulating the DNA-damage response.
    Luo Y; Leverson JD
    Expert Rev Anticancer Ther; 2005 Apr; 5(2):333-42. PubMed ID: 15877529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. UCN-01 inhibits p53 up-regulation and abrogates gamma-radiation-induced G(2)-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1.
    Yu Q; La Rose J; Zhang H; Takemura H; Kohn KW; Pommier Y
    Cancer Res; 2002 Oct; 62(20):5743-8. PubMed ID: 12384533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chk1 is dispensable for G2 arrest in response to sustained DNA damage when the ATM/p53/p21 pathway is functional.
    Lossaint G; Besnard E; Fisher D; Piette J; Dulić V
    Oncogene; 2011 Oct; 30(41):4261-74. PubMed ID: 21532626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiation-induced phosphorylation of Chk1 at S345 is associated with p53-dependent cell cycle arrest pathways.
    Tian H; Faje AT; Lee SL; Jorgensen TJ
    Neoplasia; 2002; 4(2):171-80. PubMed ID: 11896572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A subset of cancer cell lines is acutely sensitive to the Chk1 inhibitor MK-8776 as monotherapy due to CDK2 activation in S phase.
    Sakurikar N; Thompson R; Montano R; Eastman A
    Oncotarget; 2016 Jan; 7(2):1380-94. PubMed ID: 26595527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Checkpoint kinase inhibitors: a review of the patent literature.
    Janetka JW; Ashwell S
    Expert Opin Ther Pat; 2009 Feb; 19(2):165-97. PubMed ID: 19441917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blocking Chk1 expression induces apoptosis and abrogates the G2 checkpoint mechanism.
    Luo Y; Rockow-Magnone SK; Kroeger PE; Frost L; Chen Z; Han EK; Ng SC; Simmer RL; Giranda VL
    Neoplasia; 2001; 3(5):411-9. PubMed ID: 11687952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of Chk1 by the G2 DNA damage checkpoint inhibitor isogranulatimide.
    Jiang X; Zhao B; Britton R; Lim LY; Leong D; Sanghera JS; Zhou BB; Piers E; Andersen RJ; Roberge M
    Mol Cancer Ther; 2004 Oct; 3(10):1221-7. PubMed ID: 15486189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel indication for cancer therapy: Chk1 inhibition sensitizes tumor cells to antimitotics.
    Xiao Z; Xue J; Semizarov D; Sowin TJ; Rosenberg SH; Zhang H
    Int J Cancer; 2005 Jul; 115(4):528-38. PubMed ID: 15688426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy.
    McNeely S; Beckmann R; Bence Lin AK
    Pharmacol Ther; 2014 Apr; 142(1):1-10. PubMed ID: 24140082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.